Testosterone gel - Biolab Sanus Farmaceutica
Latest Information Update: 16 Feb 2016
At a glance
- Originator Biolab Sanus Farmaceutica
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone agonists; Testosterone congener stimulants; Testosterone replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Menopausal syndrome
Most Recent Events
- 16 Feb 2016 Biolab Sanus plans a phase I trial in Post-menopausal women in Brazil (NCT02667561)